US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce
AZ’s planned Alexion acquisition may be an early target
Executive Summary
Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.
You may also be interested in...
AstraZeneca Clears Final Hurdle To Seal Alexion Takeover
Antitrust authorities in the UK have followed their counterparts in the EU, Japan and the US to approve the AstraZeneca and Alexion link-up, the biggest pharma M&A deal of 2020.
Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
How AstraZeneca Overcame US Anti-Trust Obstacles For Alexion Deal
While the sector is gripped by fears that overly zealous anti-competition regulators pose a threat to future M&A biopharma deals, AstraZeneca's acquisition of Alexion has sauntered through the US FTC's review. Its CFO Marc Dunoyer tells Scrip why the company is not surprised.